Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $18.65

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) gapped up before the market opened on Tuesday . The stock had previously closed at $18.65, but opened at $19.86. Calliditas Therapeutics AB (publ) shares last traded at $19.87, with a volume of 893 shares changing hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Stock Performance

The company has a fifty day moving average of $20.80 and a two-hundred day moving average of $20.65. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 2.89.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last released its earnings results on Wednesday, February 21st. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. Calliditas Therapeutics AB (publ) had a negative return on equity of 104.47% and a negative net margin of 38.72%. The business had revenue of $42.45 million for the quarter, compared to analyst estimates of $36.24 million. During the same quarter last year, the firm posted ($0.01) earnings per share. Sell-side analysts forecast that Calliditas Therapeutics AB will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. bought a new position in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 980 shares of the company’s stock, valued at approximately $25,000. 2.83% of the stock is owned by hedge funds and other institutional investors.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.